Bausch

Valeant to drop deal-making in near term to cut debt, boost stock

Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics